Seth Loring Harrison - Oct 25, 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Director
Signature
/s/ Jonathan Young, attorney-in-fact
Stock symbol
AKRO
Transactions as of
Oct 25, 2022
Transactions value $
-$12,193,196
Form type
4
Date filed
10/27/2022, 09:50 PM
Previous filing
Jun 8, 2022
Next filing
Nov 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Sale -$203K -4.52K -1.48% $44.92 301K Oct 25, 2022 Direct F1, F2, F3
transaction AKRO Common Stock Sale -$220K -4.91K -1.48% $44.92 327K Oct 25, 2022 See Footnote F1, F2, F3, F4
transaction AKRO Common Stock Sale -$1.54M -35.9K -11.92% $43.08 265K Oct 26, 2022 Direct F2, F3, F5
transaction AKRO Common Stock Sale -$507K -11.5K -4.35% $43.97 253K Oct 26, 2022 Direct F2, F3, F6
transaction AKRO Common Stock Sale -$830K -18.5K -7.29% $44.90 235K Oct 26, 2022 Direct F2, F3, F7
transaction AKRO Common Stock Sale -$1.68M -39K -11.92% $43.08 288K Oct 26, 2022 See Footnote F2, F3, F4, F5
transaction AKRO Common Stock Sale -$551K -12.5K -4.36% $43.97 275K Oct 26, 2022 See Footnote F2, F3, F4, F6
transaction AKRO Common Stock Sale -$902K -20.1K -7.3% $44.90 255K Oct 26, 2022 See Footnote F2, F3, F4, F7
transaction AKRO Common Stock Sale -$1.68M -40.9K -17.41% $41.12 194K Oct 27, 2022 Direct F2, F3, F8
transaction AKRO Common Stock Sale -$918K -21.8K -11.25% $42.03 172K Oct 27, 2022 Direct F2, F3, F9
transaction AKRO Common Stock Sale -$160K -3.69K -2.14% $43.23 169K Oct 27, 2022 Direct F2, F3, F10
transaction AKRO Common Stock Sale -$1.83M -44.4K -17.41% $41.12 211K Oct 27, 2022 See Footnote F2, F3, F4, F8
transaction AKRO Common Stock Sale -$997K -23.7K -11.25% $42.03 187K Oct 27, 2022 See Footnote F2, F3, F4, F9
transaction AKRO Common Stock Sale -$173K -4.01K -2.15% $43.23 183K Oct 27, 2022 See Footnote F2, F3, F4, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.80 to $45.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (5), (6), (7), (8), (9) and (10) to this Form 4.
F2 The shares reported herein give effect to the pro rata distribution of shares by ATP Life Science Ventures, L.P. ("ATP," and formerly known as Apple Tree Partners IV, L.P.), for no additional consideration to its limited partners, including the reporting person, its sole general partner, ATP III GP, Ltd. ("ATP GP"), for which the reporting person is the sole director, and Les Pommes, LLC, a family limited liability company for which the reporting person is the manager (the "LLC"), subsequent to the reporting person's last filing pursuant to Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16") reporting ownership of Common Stock (the "Distribution").
F3 (Continued from footnote (2)) As the Distribution constituted only a change in the form of the reporting person's beneficial ownership of such shares, the reporting person was not required to report the Distribution pursuant to Section 16. The reporting person's beneficial ownership reported in Table I includes 305,366 shares held directly by the reporting person and 331,719 shares held directly by the LLC as a result of the Distribution.
F4 Represents shares held directly by the LLC. The reporting person is the manager of the LLC.
F5 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.63 to $43.625, inclusive.
F6 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.63 to $44.615, inclusive.
F7 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.635 to $45.14, inclusive.
F8 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.72 to $41.715, inclusive.
F9 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.72 to $42.715, inclusive.
F10 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.72 to $43.495, inclusive.